A randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability and pharmacokinetics of an oral formulation of TUR-004 in healthy adult subjects
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2015
At a glance
- Drugs TUR 004 (Primary)
- Indications Generalised seizures
- Focus Adverse reactions
- 16 Nov 2015 According to a Turing Pharmaceuticals media release, dosing of the first group of subjects has been initiated.
- 16 Nov 2015 Status changed from not yet recruiting to recruiting, as reported in a Turing Pharmaceuticals media release.
- 12 Nov 2015 According to a Turing Pharmaceuticals media release, FDA granted Fast Tack Designation to TUR-004.